Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

She had been diagnosed as having metastatic pulmonary neuroendocrine tumor. The patient's medical and family history was unremarkable; she had, however, smoked more than 20 cigarettes per day for ...

Median PFS improved from 11.5 months with single-agent everolimus to 29.7 months with the addition of lanreotide. Objective responses occurred about three times as often with the ...

Carney, Dana R., Amy J.C. Cuddy, and Andy J. Yap. "Power Posing: Brief Nonverbal Displays Affect Neuroendocrine Levels and Risk Tolerance." Psychological Science 21 ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. | On second thought, the FDA figures it ...

Pathologist Michael Roehrl is part of a multidisciplinary team that evaluates and treats hundreds of people with neuroendocrine tumors every year. At Memorial Sloan Kettering Cancer Center, our ...

A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, Ph.D., has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat ...

Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

It is known that mitochondrial unfolded protein response (UPRmt), initiated by the transcription factor ATF5, maintains protein homeostasis under stress conditions by folding denatured proteins, ...